IntelliChem Names Mike Seashols to Board of Directors
IntelliChem, Inc, the leading provider of intelligent electronic lab notebooks (iELN) for drug discovery and development, today announced that Mike Seashols has joined the company’s board of directors.
During his career, Seashols has been a successful operating executive, instrumental in the growth and IPOs of several of the software industry’s leading companies, including Documentum and Oracle Corporation.
The appointment of Seashols coincides with IntelliChem’s expansion beyond drug development into drug discovery and the clinical supply chain. As global pharmaceutical companies deploy IntelliChem iELN solutions more and more broadly across their research and development organizations, the IntelliChem management team will benefit greatly from the guidance and strategic advice that Mike Seashols has to offer.
As the initial CEO of Documentum, Seashols formulated the strategy and hired the key executive team that enabled the company to deeply penetrate the regulated pharmaceutical industry with an enterprise content management platform. Under his leadership, Documentum set the industry standard that remains even today, with the company counting nearly every major pharmaceutical company as a customer.
In addition to Documentum (IPO in 1996), Seashols spent over 10 years at IBM, followed by becoming the first vice president of sales and marketing at Oracle Corporation (IPO in 1986), founder and CEO at Versant (IPO in 1998), CEO at Evolve Software (IPO in 2001), and most recently, CEO of GoldenGate Software. In addition to IntelliChem, Seashols currently serves on the corporate boards of several privately held companies, including Velosel, Callixa, and LCN Technology.
“I am delighted to welcome Mike Seashols to the IntelliChem board,” said Dr. Paul van Eikeren, President & CEO of IntelliChem. “His extensive experience in growing enterprise software companies will help guide IntelliChem through our next phase of growth. Plus, his experience in creating standards across the regulated pharmaceutical industry will provide strong guidance for IntelliChem as we strive to achieve the same objective. With Mike retiring here in Bend, Oregon, we are excited to tap such an experienced industry veteran right in our backyard.”
“Electronic lab notebooks for the pharmaceutical and biotechnology industries represent one of the next major enterprise software markets and IntelliChem is quickly emerging as the market leader,” said Mike Seashols, newly appointed board member, IntelliChem. “With its compelling customer base, broad product offerings, strong management team, and financial backing from Summit Partners, IntelliChem is poised for tremendous growth. I look forward to playing a key role in helping IntelliChem leverage its leading position in this exciting growth market.”
About Intelligent Electronic Laboratory Notebooks
Spending on research and development in the pharmaceutical and biotechnology industries has increased dramatically over the past decade without a corresponding pipeline of new products, driving the industry to find ways of dramatically improving productivity and efficiency. Many leading companies have concluded that replacing paper lab notebooks with intelligent, searchable systems is key to these improvements. Intelligent electronic lab notebooks (iELN) not only allow companies to replace paper lab notebooks, but they also provide collaborative decision-support tools to help scientists and engineers make better decisions, delivering the required benefits that pharmaceutical and biotechnology companies require to gain competitive advantage.
About IntelliChem
IntelliChem, Inc. is the leading provider of intelligent electronic lab notebooks (iELN) for discovery and development. Pharmaceutical, biotechnology, and fine chemicals companies can improve productivity, enable collaboration, improve quality, and ensure regulatory compliance through the adoption of IntelliChem solutions. IntelliChem Discovery & Development Solutions (IDS) were developed and validated through partnership with six major pharmaceutical companies, including Merck & Co., Pfizer, and Bristol-Myers Squibb. IntelliChem is a privately held company with headquarters and development facilities located in Bend, Oregon. For more information, visit www.intellichem.com .
